2025 Q4 -tulosraportti
Vain PDF
75 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 209 | - | - | ||
| 14 | - | - | ||
| 12 | - | - | ||
| 1 039 | - | - | ||
| 153 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5.5. · Muokattu😊 – I've had fun with some statistics together with 2 different AI models to find probabilities for all outcomes of the 5 main projects (Acadia, Jazz + 3 inhouse), so one is nicely free from having emotions involved in the game. Individual LoA’s per asset have been used – partly a "std" source, which apparently should be "Clinical Development Succes Rates and Contribution Factors 2011-2020" from "Biotechnology Innovation Organization" – and partly Redeye’s LoA. I then asked for a statistical probability for all outcomes between 0/5 and 5/0 (When the market/fails). Reportedly, it should involve a "Bernoulli Trial" and a "Poisson-binomial model" :-) - the former I have never heard of, the models I can vaguely recall from the happy and carefree student days at the Business School some decades ago :-) Then I get approximately these outcomes (Redeye / "industry standard"): 0/5: 51,9 / 68,9 1/4: 34,8 / 27,4 2/3: 10,9 / 3,5 3/2: 2,0 / 0,2 4/1: 0,2 / 0,005 5/5: 0,01 / 0,0001 Fun little experiment 😊 I went a bit further, but it became a bit more extensive - something about whether there could be a correlation between the different assets, so if 1 fails, it might have something to do with mechanisms of action and such - and also weighted whether it was a partner or not - but it is fun :-)
·6.5.Saniona can indeed earn a lot of money without requiring the products to reach the market (e.g., via partnership), and Saniona can be acquired for large billion amounts WITHOUT any of the projects having reached the market - but e.g. if "just" 2 of their 3 main projects reach phase 2. And what would be the probability of that? That's probably more relevant than painting the devil on the wall :)
·24.4.Today's scam now AGAIN 😴😴🥱🥱🥱·4.5. · MuokattuThinking that the bottom has been reached and the journey towards 30 kr. begins.·4.5. · MuokattuAhhh probably not 30 anytime soon, but anything can happen with that management, as one can see ,there's something wrong with the communication to the market when there's something positive and and when "not yet approved" , and "very short time, maybe not a month before approval" it seems somewhat rotten from the management. Maybe they are in on something ?- 28.4.28.4.Tämä julkaisu on poistettu.
·23.4.Well, surely there must be news coming from the company or a larger player who sees the value, and buys while it's still cheap ;-)·23.4. · MuokattuJust imagine where the price ends up with 2-4% down EVERY day and endless silence from management, that is IF there is a management 🤔🙄 two more months of silence, well then we can do the math. Clearly a super good deal can probably temporarily pull us up to 17-18 kr 😂😂😂 - ·21.4.Stig B. Try to take a look at Ascelia, Gentian and Observe Medicals·21.4.Hmm - as a high risk/reward position, Observe could be a bit fun, if they can partially reclaim the Convatec market. Sounds like a bit of a task, though, and it also seems that execution power is low - both resource-wise and experience-wise when looking at the organization (management, size, and board). I'll have to look into that a bit more - but it sounds fun/exciting. Gantian, I need to look into a bit more - it seems to be more of a "proven case".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
75 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5.5. · Muokattu😊 – I've had fun with some statistics together with 2 different AI models to find probabilities for all outcomes of the 5 main projects (Acadia, Jazz + 3 inhouse), so one is nicely free from having emotions involved in the game. Individual LoA’s per asset have been used – partly a "std" source, which apparently should be "Clinical Development Succes Rates and Contribution Factors 2011-2020" from "Biotechnology Innovation Organization" – and partly Redeye’s LoA. I then asked for a statistical probability for all outcomes between 0/5 and 5/0 (When the market/fails). Reportedly, it should involve a "Bernoulli Trial" and a "Poisson-binomial model" :-) - the former I have never heard of, the models I can vaguely recall from the happy and carefree student days at the Business School some decades ago :-) Then I get approximately these outcomes (Redeye / "industry standard"): 0/5: 51,9 / 68,9 1/4: 34,8 / 27,4 2/3: 10,9 / 3,5 3/2: 2,0 / 0,2 4/1: 0,2 / 0,005 5/5: 0,01 / 0,0001 Fun little experiment 😊 I went a bit further, but it became a bit more extensive - something about whether there could be a correlation between the different assets, so if 1 fails, it might have something to do with mechanisms of action and such - and also weighted whether it was a partner or not - but it is fun :-)·6.5.Saniona can indeed earn a lot of money without requiring the products to reach the market (e.g., via partnership), and Saniona can be acquired for large billion amounts WITHOUT any of the projects having reached the market - but e.g. if "just" 2 of their 3 main projects reach phase 2. And what would be the probability of that? That's probably more relevant than painting the devil on the wall :)
- ·24.4.Today's scam now AGAIN 😴😴🥱🥱🥱·4.5. · MuokattuThinking that the bottom has been reached and the journey towards 30 kr. begins.·4.5. · MuokattuAhhh probably not 30 anytime soon, but anything can happen with that management, as one can see ,there's something wrong with the communication to the market when there's something positive and and when "not yet approved" , and "very short time, maybe not a month before approval" it seems somewhat rotten from the management. Maybe they are in on something ?
- 28.4.28.4.Tämä julkaisu on poistettu.·23.4.Well, surely there must be news coming from the company or a larger player who sees the value, and buys while it's still cheap ;-)·23.4. · MuokattuJust imagine where the price ends up with 2-4% down EVERY day and endless silence from management, that is IF there is a management 🤔🙄 two more months of silence, well then we can do the math. Clearly a super good deal can probably temporarily pull us up to 17-18 kr 😂😂😂
- ·21.4.Stig B. Try to take a look at Ascelia, Gentian and Observe Medicals·21.4.Hmm - as a high risk/reward position, Observe could be a bit fun, if they can partially reclaim the Convatec market. Sounds like a bit of a task, though, and it also seems that execution power is low - both resource-wise and experience-wise when looking at the organization (management, size, and board). I'll have to look into that a bit more - but it sounds fun/exciting. Gantian, I need to look into a bit more - it seems to be more of a "proven case".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 209 | - | - | ||
| 14 | - | - | ||
| 12 | - | - | ||
| 1 039 | - | - | ||
| 153 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
75 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5.5. · Muokattu😊 – I've had fun with some statistics together with 2 different AI models to find probabilities for all outcomes of the 5 main projects (Acadia, Jazz + 3 inhouse), so one is nicely free from having emotions involved in the game. Individual LoA’s per asset have been used – partly a "std" source, which apparently should be "Clinical Development Succes Rates and Contribution Factors 2011-2020" from "Biotechnology Innovation Organization" – and partly Redeye’s LoA. I then asked for a statistical probability for all outcomes between 0/5 and 5/0 (When the market/fails). Reportedly, it should involve a "Bernoulli Trial" and a "Poisson-binomial model" :-) - the former I have never heard of, the models I can vaguely recall from the happy and carefree student days at the Business School some decades ago :-) Then I get approximately these outcomes (Redeye / "industry standard"): 0/5: 51,9 / 68,9 1/4: 34,8 / 27,4 2/3: 10,9 / 3,5 3/2: 2,0 / 0,2 4/1: 0,2 / 0,005 5/5: 0,01 / 0,0001 Fun little experiment 😊 I went a bit further, but it became a bit more extensive - something about whether there could be a correlation between the different assets, so if 1 fails, it might have something to do with mechanisms of action and such - and also weighted whether it was a partner or not - but it is fun :-)·6.5.Saniona can indeed earn a lot of money without requiring the products to reach the market (e.g., via partnership), and Saniona can be acquired for large billion amounts WITHOUT any of the projects having reached the market - but e.g. if "just" 2 of their 3 main projects reach phase 2. And what would be the probability of that? That's probably more relevant than painting the devil on the wall :)
- ·24.4.Today's scam now AGAIN 😴😴🥱🥱🥱·4.5. · MuokattuThinking that the bottom has been reached and the journey towards 30 kr. begins.·4.5. · MuokattuAhhh probably not 30 anytime soon, but anything can happen with that management, as one can see ,there's something wrong with the communication to the market when there's something positive and and when "not yet approved" , and "very short time, maybe not a month before approval" it seems somewhat rotten from the management. Maybe they are in on something ?
- 28.4.28.4.Tämä julkaisu on poistettu.·23.4.Well, surely there must be news coming from the company or a larger player who sees the value, and buys while it's still cheap ;-)·23.4. · MuokattuJust imagine where the price ends up with 2-4% down EVERY day and endless silence from management, that is IF there is a management 🤔🙄 two more months of silence, well then we can do the math. Clearly a super good deal can probably temporarily pull us up to 17-18 kr 😂😂😂
- ·21.4.Stig B. Try to take a look at Ascelia, Gentian and Observe Medicals·21.4.Hmm - as a high risk/reward position, Observe could be a bit fun, if they can partially reclaim the Convatec market. Sounds like a bit of a task, though, and it also seems that execution power is low - both resource-wise and experience-wise when looking at the organization (management, size, and board). I'll have to look into that a bit more - but it sounds fun/exciting. Gantian, I need to look into a bit more - it seems to be more of a "proven case".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 209 | - | - | ||
| 14 | - | - | ||
| 12 | - | - | ||
| 1 039 | - | - | ||
| 153 | - | - |
Välittäjätilasto
Dataa ei löytynyt